Showing results (151-160 of 255) with videos related to
Sort By:
Pageof 26
Pediatric Blood & Cancer|August 19, 2014
Surgical management of thymic epithelial tumors in children: lessons from the French Society of Pediatric Oncology and review of the literatureJ Rod, D Orbach, C Verité, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2010
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?C Massard, A Plantade, M Gross-Goupil, et al.Cancer Chemotherapy and Pharmacology|November 16, 2006
Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over studyE G C Brain, K Rezai, S Weill, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2007
High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activityK Fizazi, L Morat, L Chauveinc, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2007
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave RoussyA Italiano, C Massard, R Bahleda, et al.European Journal of Cancer (Oxford, England : 1990)|July 15, 2010
Prevalence and causes of burnout amongst oncology residents: a comprehensive nationwide cross-sectional studyP Blanchard, D Truchot, L Albiges-Sauvin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2000
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancerK Fizazi, M Ducreux, P Ruffié, et al.Investigational New Drugs|January 5, 2012
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumorsC Massard, R Salazar, J P Armand, et al.European Journal of Cancer (Oxford, England : 1990)|June 23, 2009
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancersJ C Soria, C Massard, N Magné, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2007
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trialsR Conforti, T Boulet, G Tomasic, et al.Pageof 26